Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
NCT Number: NCT07574866
Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging and the frequent emergence of drug-resistant bacteria; in China, severe pneumonia accounts for a striking 13.58% to 20.05% of hospitalized cases. In recent years, shifts in the pathogen spectrum (e.g., COVID-19, influenza A) and patient demographic characteristics have posed new challenges for clinical management. However, existing studies mostly focus on single pathogens or specific populations (e.g., ICU patients), lacking systematic analyses of the full-disease course characteristics of general hospitalized pneumonia patients. Furthermore, in the post-pandemic era, the clinical phenotypes, treatment responses, and prognostic factors of pneumonia may have evolved, necessitating evidence-based support from real-world data. This study aims to conduct a retrospective analysis to clarify the epidemiological characteristics, etiological distribution, and prognostic factors influencing current hospitalized pneumonia patients, thereby providing a basis for optimizing diagnosis and treatment strategies.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Guangzhou, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for the severe group:
A diagnosis of "severe pneumonia" can be made if one of the main criteria or ≥ 3 of the secondary criteria are met.
Main criteria:
① Tracheal intubation requiring mechanical ventilation
② Need for vasoactive drugs after active fluid resuscitation for septic shock
Secondary criteria:
⑥ Leukopenia (WBC < 4×10⁹/L)
Exclusion criteria
Time frame: 28 days after admission
Time frame: 28 days after admission
Demographic data (age, sex, etc.)
Time frame: 28 days after admission
Comorbidities, such as chronic obstructive pulmonary disease (COPD), diabetes mellitus, and cardiovascular diseases.
Time frame: 28 days after admission
Symptomatic manifestations (e.g., fever, cough, dyspnea)
Time frame: 28 days after admission
Laboratory tests (including blood routine, liver and kidney function, etc.)
Time frame: 28 days after admission
Imaging Examination: Radiological manifestations and image data from chest X-ray or CT scans
Time frame: 28 days after admission
Time frame: 28 days after admission
Time frame: 28 days after admission
Time frame: 28 days after admission
Time frame: 28 days after admission
Contact information is provided by the study sponsor or research team.
Zhonghao Fang
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07708610
Diabetes Mellitus, Diabetes Mellitus, Type 2
Taichung, Taiwan
View Trial DetailsNCT07703852
Infections, Lung Diseases
View Trial DetailsNCT07631377
Actinomycetales Infections, Antibiotic Resistant Strain
View Trial DetailsNCT07634419
ARDS, Accidental Injuries
Los Angeles, California, United States
View Trial Details